CPP (Cancer Prevention Pharmaceuticals) Scaled Net Operating Assets : -14.02 (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cancer Prevention Pharmaceuticals's operating assets for the quarter that ended in Mar. 2016 was $0.50 Mil. Cancer Prevention Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2016 was $26.44 Mil. Cancer Prevention Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2015 was $1.85 Mil. Therefore, Cancer Prevention Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2016 was -14.02.

Cancer Prevention Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Scaled Net Operating Assets Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Scaled Net Operating Assets

-5.97

-10.33

-4.66

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Scaled Net Operating Assets	Get a 7-Day Free Trial			-	-	-	-7.18	-14.02

Competitive Comparison of Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets falls into.

Save Embed

;

Save Embed

;

Cancer Prevention Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2015 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2015 )
=	(Operating Assets (A: Dec. 2015 )	-	Operating Liabilities (A: Dec. 2015 ))	/	Total Assets (A: Dec. 2014 )
=	(0.369	-	23.032)	/	4.86
=	-4.66

where

	Operating Assets		(A: Dec. 2015 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	1.85	-	1.481
=	0.369

	Operating Liabilities		(A: Dec. 2015 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	23.032	-	0	-	0
=	23.032

Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2016 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2016 )
=	(Operating Assets (Q: Mar. 2016 )	-	Operating Liabilities (Q: Mar. 2016 ))	/	Total Assets (Q: Dec. 2015 )
=	(0.497	-	26.436)	/	1.85
=	-14.02

where

	Operating Assets		(Q: Mar. 2016 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	9.189	-	8.692
=	0.497

	Operating Liabilities		(Q: Mar. 2016 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	32.039	-	5.603	-	0
=	26.436

Cancer Prevention Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.